Literature DB >> 26306765

Fibromyalgia syndrome in need of effective treatments.

Theoharis C Theoharides1, Irene Tsilioni2, Lauren Arbetman2, Smaro Panagiotidou2, Julia M Stewart2, Rae M Gleason2, Irwin J Russell2.   

Abstract

Fibromyalgia syndrome (FMS) is a chronic, idiopathic condition of widespread musculoskeletal pain, affecting primarily women. It is clinically characterized by chronic, nonarticular pain and a heightened response to pressure along with sleep disturbances, fatigue, bowel and bladder abnormalities, and cognitive dysfunction. The diagnostic criteria have changed repeatedly, and there is neither a definitive pathogenesis nor reliable diagnostic or prognostic biomarkers. Clinical and laboratory studies have provided evidence of altered central pain pathways. Recent evidence suggests the involvement of neuroinflammation with stress peptides triggering the release of neurosenzitizing mediators. The management of FMS requires a multidimensional approach including patient education, behavioral therapy, exercise, and pain management. Here we review recent data on the pathogenesis and propose new directions for research and treatment.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26306765      PMCID: PMC4613957          DOI: 10.1124/jpet.115.227298

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  159 in total

Review 1.  Chemokines, chemokine receptors and pain.

Authors:  Catherine Abbadie
Journal:  Trends Immunol       Date:  2005-10       Impact factor: 16.687

2.  The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells.

Authors:  Zuyi Weng; Arti B Patel; Smaro Panagiotidou; Theoharis C Theoharides
Journal:  J Allergy Clin Immunol       Date:  2014-12-10       Impact factor: 10.793

3.  Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia.

Authors:  Samuel A McLean; David A Williams; Phyllis K Stein; Richard E Harris; Angela K Lyden; Gail Whalen; Karen M Park; Israel Liberzon; Ananda Sen; Richard H Gracely; James N Baraniuk; Daniel J Clauw
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

4.  COMT moderates the relation of daily maladaptive coping and pain in fibromyalgia.

Authors:  Patrick H Finan; Alex J Zautra; Mary C Davis; Kathryn Lemery-Chalfant; Jonathan Covault; Howard Tennen
Journal:  Pain       Date:  2010-12-03       Impact factor: 6.961

5.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

6.  IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation.

Authors:  Gabriel K Griffin; Gail Newton; Margarite L Tarrio; De-xiu Bu; Elena Maganto-Garcia; Veronica Azcutia; Pilar Alcaide; Nir Grabie; Francis W Luscinskas; Kevin J Croce; Andrew H Lichtman
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

7.  Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Authors:  Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold
Journal:  Pain       Date:  2008-04-18       Impact factor: 6.961

8.  DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls.

Authors:  Stéphane Potvin; Annie Larouche; Edith Normand; Juliana Barcellos de Souza; Isabelle Gaumond; Sylvain Grignon; Serge Marchand
Journal:  J Pain       Date:  2009-05-23       Impact factor: 5.820

Review 9.  Mast cells: versatile gatekeepers of pain.

Authors:  Devavani Chatterjea; Tijana Martinov
Journal:  Mol Immunol       Date:  2014-03-22       Impact factor: 4.407

10.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

View more
  22 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 2.  Fibromyalgia Pathogenesis and Treatment Options Update.

Authors:  Steven Chinn; William Caldwell; Karina Gritsenko
Journal:  Curr Pain Headache Rep       Date:  2016-04

Review 3.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

4.  Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Young Ho Lee; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

5.  Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells.

Authors:  Irene Tsilioni; Irwin J Russell; Julia M Stewart; Rae M Gleason; Theoharis C Theoharides
Journal:  J Pharmacol Exp Ther       Date:  2016-01-13       Impact factor: 4.030

6.  Efficacy of baths with mineral-medicinal water in patients with fibromyalgia: a randomized clinical trial.

Authors:  María Reyes Pérez-Fernández; Natalia Calvo-Ayuso; Cristina Martínez-Reglero; Ángel Salgado-Barreira; José Luis Muiño López-Álvarez
Journal:  Int J Biometeorol       Date:  2019-06-03       Impact factor: 3.787

7.  Serum Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome.

Authors:  Ahmet Karadağ; Emrullah Hayta; Veysel Kenan Çelik; Sevtap Bakir
Journal:  Arch Rheumatol       Date:  2019-04-22       Impact factor: 1.472

8.  Functional MRI of the Reserpine-Induced Putative Rat Model of Fibromyalgia Reveals Discriminatory Patterns of Functional Augmentation to Acute Nociceptive Stimuli.

Authors:  Jack A Wells; Sayaka Shibata; Akihiko Fujikawa; Masayasu Takahashi; Tsuneo Saga; Ichio Aoki
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

9.  Signs of ongoing inflammation in female patients with chronic widespread pain: A multivariate, explorative, cross-sectional study of blood samples.

Authors:  Björn Gerdle; Bijar Ghafouri; Nazdar Ghafouri; Emmanuel Bäckryd; Torsten Gordh
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  Serum cortisol and dehydroepiandrosterone-sulfate levels after balneotherapy and physical therapy in patients with fibromyalgia.

Authors:  Esra A Semiz; Sami Hizmetli; Murat Semiz; Ahmet Karadağ; Merve Adalı; Mehmet S Tuncay; Bulent Alim; Emrullah Hayta; Ali U Uslu
Journal:  Saudi Med J       Date:  2016-05       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.